Tags

Type your tag names separated by a space and hit enter

Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
Vaccine. 2007 Apr 20; 25(16):3118-23.V

Abstract

Vaccines against yellow fever currently recommended by the World Health Organization contain either virus sub-strains 17D or 17DD. In adults, the 17DD vaccine demonstrated high seroconversion and similar performance to vaccines manufactured with the WHO 17D-213/77 seed-lot. In another study, 17DD vaccine showed lower seroconversion rates in children younger than 2 years. Data also suggested lower seroconversion with simultaneous application of measles vaccine. This finding in very young children is not consistent with data from studies with 17D vaccines. A multicenter, randomized, double-blind clinical trial was designed (1) to compare the immunogenicity and reactogenicity of two yellow fever vaccines: 17DD (licensed product) and 17D-213/77 (investigational product) in children aged 9-23 months; (2) to assess the effect of simultaneous administration of yellow fever and the measles-mumps-rubella vaccines; and (3) to investigate the interference of maternal antibodies in the response to yellow fever vaccination. The anticipated implications of the results are changes in vaccine sub-strains used in manufacturing YF vaccine used in several countries and changes in the yellow fever vaccination schedule recommendations in national immunization programs.

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17316925

Citation

Collaborative Group for Studies with Yellow Fever Vaccine. "Randomized, Double-blind, Multicenter Study of the Immunogenicity and Reactogenicity of 17DD and WHO 17D-213/77 Yellow Fever Vaccines in Children: Implications for the Brazilian National Immunization Program." Vaccine, vol. 25, no. 16, 2007, pp. 3118-23.
Collaborative Group for Studies with Yellow Fever Vaccine. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program. Vaccine. 2007;25(16):3118-23.
Collaborative Group for Studies with Yellow Fever Vaccine. (2007). Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program. Vaccine, 25(16), 3118-23.
Collaborative Group for Studies with Yellow Fever Vaccine. Randomized, Double-blind, Multicenter Study of the Immunogenicity and Reactogenicity of 17DD and WHO 17D-213/77 Yellow Fever Vaccines in Children: Implications for the Brazilian National Immunization Program. Vaccine. 2007 Apr 20;25(16):3118-23. PubMed PMID: 17316925.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program. A1 - ,, Y1 - 2007/01/22/ PY - 2007/2/24/pubmed PY - 2007/7/11/medline PY - 2007/2/24/entrez SP - 3118 EP - 23 JF - Vaccine JO - Vaccine VL - 25 IS - 16 N2 - Vaccines against yellow fever currently recommended by the World Health Organization contain either virus sub-strains 17D or 17DD. In adults, the 17DD vaccine demonstrated high seroconversion and similar performance to vaccines manufactured with the WHO 17D-213/77 seed-lot. In another study, 17DD vaccine showed lower seroconversion rates in children younger than 2 years. Data also suggested lower seroconversion with simultaneous application of measles vaccine. This finding in very young children is not consistent with data from studies with 17D vaccines. A multicenter, randomized, double-blind clinical trial was designed (1) to compare the immunogenicity and reactogenicity of two yellow fever vaccines: 17DD (licensed product) and 17D-213/77 (investigational product) in children aged 9-23 months; (2) to assess the effect of simultaneous administration of yellow fever and the measles-mumps-rubella vaccines; and (3) to investigate the interference of maternal antibodies in the response to yellow fever vaccination. The anticipated implications of the results are changes in vaccine sub-strains used in manufacturing YF vaccine used in several countries and changes in the yellow fever vaccination schedule recommendations in national immunization programs. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/17316925/Randomized_double_blind_multicenter_study_of_the_immunogenicity_and_reactogenicity_of_17DD_and_WHO_17D_213/77_yellow_fever_vaccines_in_children:_implications_for_the_Brazilian_National_Immunization_Program_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(07)00067-9 DB - PRIME DP - Unbound Medicine ER -